Send to

Choose Destination
See comment in PubMed Commons below
J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548. Epub 2012 Jul 11.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

Author information

  • 1Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.



Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11.


Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period.


Both ligands displayed highly significant group discrimination and correlation of regional uptake.


These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk